Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHEZF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.36 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Shenzhen Hepalink Pharmaceutical Group Co (OTCPK:SHEZF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Shenzhen Hepalink Pharmaceutical Group Co 5-Year Yield-on-Cost % Related Terms
SHEZF vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Hepalink Pharmaceutical Group Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shenzhen Hepalink Pharmaceutical Group Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Shenzhen Hepalink Pharmaceutical Group Co's 5-Year Yield-on-Cost % falls into.
Shenzhen Hepalink Pharmaceutical Group Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 25, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. Over the past decade, Shenzhen Hepalink Pharmaceutical Group Co's 5-Year Yield-on-Cost % has ranged from 0.17 to 2.89. According to the industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #312 out of 513 companies in the Drug Manufacturers industry, placing it in the top 60.8%.
Is Shenzhen Hepalink Pharmaceutical Group Co's 5-Year Yield-on-Cost % too high?
Shenzhen Hepalink Pharmaceutical Group Co's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 2.89. Based on the distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #312 out of 513 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #312 out of 513 companies for 5-Year Yield-on-Cost %. This places Shenzhen Hepalink Pharmaceutical Group Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.36. Historically, Shenzhen Hepalink Pharmaceutical Group Co's own 5-Year Yield-on-Cost % has ranged from 0.17 to 2.89 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.36, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Hepalink Pharmaceutical Group Co's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is $0.57, compared to a current price of $0.47 — trading 17.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of $0.47 is trading 17.6% below its estimated GF Value™ of $0.57.
Key valuation signals for SHEZF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $0.57 vs. price of $0.47 (17.6% below fair value)
No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Hepalink Pharmaceutical Group Co Business Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
69GF Score
Get the complete analysis for SHEZF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHEZF has been successfully added to your 
